MOLECULAR PARTNERS AG Business Summary

Molecular Partners AG (MOLN) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of proprietary drug development and high-value strategic licensing, milestone payments, and R&D partnerships. The company’s business is primarily segmented into Oncology, focusing on its pioneering Radio-DARPin platform (e.g., MP0712) and multi-specific T-cell engagers (e.g., MP0533), and Ophthalmology, alongside a flexible Infectious Disease arm. Utilizing its proprietary DARPin (Designed Ankyrin Repeat Protein) technology, the firm engineers small, modular proteins that offer higher specificity and stability than traditional antibodies. As of February 2026, Molecular Partners maintains significant collaborations with Orano Med for alpha-radiotherapies and Novartis for antiviral and oncology programs. The company competes with protein-scaffold and immunotherapy developers such as Inhibrx Biosciences, Immunocore, Fate Therapeutics, and AC Immune, distinguishing itself through its "Switch-DARPin" logic-gated activation technology and a cash runway extending into 2028. The company was founded in 2004 by a team of researchers from the University of Zurich, including Christian Zahnd, Patrick Amstutz, and Michael Tobias Stumpp, who commercialized the DARPin scaffold. The current executive team is led by CEO and Co-founder Dr. Patrick Amstutz, a prominent figure in the European life sciences sector who also serves as President of the Swiss Biotech Association. In October 2025, the leadership was further strengthened by the appointment of Chief Scientific Officer Dr. Martin Steegmaier, formerly of SOTIO Biotech and MorphoSys, while Dr. Daniel Steiner serves as SVP of Research & Technology. Other key leaders include COO Alexander Zürcher, CMO Dr. Philippe Legenne, and Co-founder Dr. Michael Tobias Stumpp (EVP Projects). The board is chaired by William M. Burns, former CEO of Roche Pharmaceuticals, and the company’s investor base features prominent names such as Index Ventures, BB Biotech Ventures, and Novartis, the latter holding a strategic equity stake.